Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

被引:55
|
作者
Leib, Edward S. [1 ]
Saag, Kenneth G. [2 ]
Adachi, Jonathan D. [3 ]
Geusens, Piet P. [4 ,5 ]
Binkley, Neil [6 ]
McCloskey, Eugene V. [7 ]
Hans, Didier B. [8 ]
机构
[1] Univ Vermont, Coll Med, Burlington, VT 05401 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada
[4] Maastricht Univ Caphri, Dept Internal Med, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[5] Univ Hasselt, Biomed Res Ctr, Hasselt, Belgium
[6] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[7] Univ Sheffield, Sheffield, S Yorkshire, England
[8] Univ Lausanne Hosp, Dept Bone & Joint, Lausanne, Switzerland
基金
英国医学研究理事会;
关键词
Glucocorticoids; fracture risk; drug-induced osteoporosis; FRAX; BONE-MINERAL DENSITY; OBSTRUCTIVE PULMONARY-DISEASE; LOW-DOSE PREDNISONE; INHALED CORTICOSTEROIDS; ADDISONS-DISEASE; REPLACEMENT THERAPY; 21-HYDROXYLASE DEFICIENCY; INDUCED OSTEOPOROSIS; ORAL GLUCOCORTICOIDS; RHEUMATOID-ARTHRITIS;
D O I
10.1016/j.jocd.2011.05.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Given the significant impact the use of glucocorticoids can have on fracture risk independent of bone density, their use has been incorporated as one of the clinical risk factors for calculating the 10-year fracture risk in the World Health Organization's Fracture Risk Assessment Tool (FRAX (R)). Like the other clinical risk factors, the use of glucocorticoids is included as a dichotomous variable with use of steroids defined as past or present exposure of 3 months or more of use of a daily dose of 5 mg or more of prednisolone or equivalent. The purpose of this report is to give clinicians guidance on adjustments which should be made to the 10-year risk based on the dose, duration of use and mode of delivery of glucocorticoid preparations. A subcommittee of the International Society for Clinical Densitometry and International Osteoporosis Foundation joint Position Development Conference presented its findings to an expert panel and the following recommendations were selected. 1) There is a dose relationship between glucocorticoid use of greater than 3 months and fracture risk. The average dose exposure captured within FRAX (R) is likely to be a prednisone dose of 2.5-7.5 mg/day or its equivalent. Fracture probability is under-estimated when prednisone dose is greater than 7.5 mg/day and is over-estimated when the prednisone dose is less than 2.5 mg/day. 2) Frequent intermittent use of higher doses of glucocorticoids increases fracture risk. Because of the variability in dose and dosing schedule, quantification of this risk is not possible. 3) High dose inhaled glucocorticoids may be a risk factor for fracture. FRAX (R) may underestimate fracture probability in users of high dose inhaled glucocorticoids. 4) Appropriate glucocorticoid replacement in individuals with adrenal insufficiency has not been found to increase fracture risk. In such patients, use of glucocorticoids should not be included in FRAX (R) calculations.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [31] FREM predicts 10-year incident fracture risk independent of FRAX® probability: a registry-based cohort study
    Leslie, William D.
    Moeller, Soren
    Skjodt, Michael K.
    Yan, Lin
    Abrahamsen, Bo
    Lix, Lisa M.
    McCloskey, Eugene, V
    Johansson, Helena
    Harvey, Nicholas C.
    Kanis, John A.
    Rubin, Katrine Hass
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (07) : 1457 - 1463
  • [32] Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture
    Bruyere, O.
    Nicolet, D.
    Compere, S.
    Rabenda, V.
    Jeholet, P.
    Zegels, B.
    Maassen, P.
    Pire, G.
    Reginster, J. Y.
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (04) : 979 - 983
  • [33] Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX®) to assess the 10-year probability of fracture
    O. Bruyère
    D. Nicolet
    S. Compère
    V. Rabenda
    P. Jeholet
    B. Zegels
    P. Maassen
    G. Pire
    J. Y. Reginster
    Rheumatology International, 2013, 33 : 979 - 983
  • [34] INCREMENTAL PREDICTIVE VALUE OF EXTENDING FRAX PREDICTORS WITH GLUCOCORTICOID DOSE AND PSYCHOTROPIC DRUGS FORTHE 10-YEAR RISK OF HIP FRACTURE
    de Vries, Frank
    Klop, Corinne
    Bazelier, Marloes
    Bijlsma, Hans
    Leutkens, Hubert
    Welsing, Paco
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : 630 - 630
  • [35] THE USE OF NECK BMD IN THE FRAX® ALGORITHMS DOES NOT ENHANCE THE PREDICTION ONTHE 10-YEAR OFABSOLUTE RISK IN MEXICAN POPULATION
    Clark, P.
    Deleze, M.
    Cons Molina, F.
    Morales Torres, J.
    Rivas-Ruiz, R.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S323 - S324
  • [37] 10-YEAR PROBABILITY OF FRAGILITY FRACTURES IN PERI- AND POSTMENOPAUSAL SAUDI WOMEN ACCORDING TO WHO FRACTURE RISK ASSESSMENT TOOL (FRAX)
    Shahi, U.
    Al Farhan, M. F.
    Shahi, N.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S446 - S447
  • [38] T-SCORE OR Z-SCORE OUGHT TO BE USED IN CALCULATION OF 10-YEAR FRACTURE RISK WITH FRAX® METHOD? POMOST STUDY
    Przedlacki, J.
    Teter, P.
    Ksiezopolska-Orlowska, K.
    Grodzki, A.
    Bartuszek, T.
    Bartuszek, D.
    Swirski, A.
    Musial, J.
    Luczak, E.
    Loth, E.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 95 - 95
  • [39] CORRELATION OF THE HIP FRACTURE 10-YEAR RISK SCORE (FRAX TOOL) WITH DIAGNOSIS OF OSTEOPOROSIS BY DXA SCAN IN FRAGILITY FRACTURE PATIENTS AT A NHS SECONDARY CARE FRACTURE LIAISON CLINIC
    Nandi, A.
    Obeichina, N.
    Javed, F.
    Nur, M.
    Johal, S.
    Butt, A.
    Sargent, G.
    Vijayenthiran, H.
    Ali, T.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S482 - S482
  • [40] FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density are we treating our patients under bDMARDs?
    Seabra Rato, M.
    Oliveira Pinheiro, F.
    Garcia, S.
    Fernandes, B.
    Bernardo, A.
    Gaio, R.
    Costa, L.
    Benardes, M.
    ARP RHEUMATOLOGY, 2023, 2 (01): : 47 - 52